| Name | Title | Contact Details |
|---|
South Bend Heritage Foundation (SBH) is a not-for-profit community development corporation that is committed to the stabilization and empowerment of our neighborhoods. Our vision is a united community where all residents have equitable and just opportu...
The journey to grow your giving begins here, whether you are an individual, family, business, professional advisor or foundation.
Offset House Inc is a Essex Junction, VT-based company in the Business Services sector.
A Canadian owned and operated business since 1990, Organika is dedicated to educating and empowering our consumers to seek the highest quality natural health solutions for their good health and wellbeing. Organika`s story began nearly thirty years ago, when founder, Thomas Chin, turned to a blend of turmeric, parsley and juice to cure his kidney stones, miraculously avoiding an extensive and extremely invasive surgery and inspiring him to share the concept of natural healing with others. Thus, Organika was born under Chin`s belief that, ailment can be cured naturally, which should be the focus of whole health. Today, our Innovation Team relies on continuous research and development in the lab, extensive market research across various industries and new ingredient discovery across the globe to anticipate health-related issues, trends and wants before they become relevant to the mainstream media, allowing us to fully satisfy the wellness needs of our heroes, the consumer. An enthusiast for inspiring the next generation, Organika CEO, Aaron Chin believes that, With more options than ever before, Organika is making it easier for consumers to shop and create a personalized self-care experience to suit their health needs, making them feel better inside and out.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.